OmarAlhalabiMD

PubMed

• Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
  Sinchita Roy-Chowdhuri, Lan Zheng, Hui Chen, Jianping Zhao, Ashish M Kamat, Omar Alhalabi, Jianjun Gao, Arlene Siefker-Radtke, Donna E Hansel, Bogdan Czerniak, Charles...> ;Human Pathology. 2024 Apr 26
• Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
  Rhenita Amirtharaj, Lianchun Xiao, Dzifa Y Duose, Shufang Wang, Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Suzanne Lange, Suma...> ;The Journal of Urology. 2024 Apr 10
• Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
  Mohammad Jad Moussa, Matthew T Campbell, Omar Alhalabi> ;Biomedicines. 2024 Feb 26
• Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
  Woo Cheal Cho, Rayan Saade, Priyadharsini Nagarajan, Phyu P Aung, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan,...> ;Journal of Cutaneous Pathology. 2024 May 1
• 1 citations
  Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
  Andrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, Tharakeswara K Bathala, Andrew J Wiele, Matthew T Campbell, Amado J Zurita, Amishi Y Shah, Eric Jonasch, Jianjun G...> ;The Oncologist. 2024 May 3
• Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center...
  Jan K Rudzinski, Craig V Labbate, Patrick J Hensley, Kelly K Bree, Charles C Guo, Omar Alhalabi, Matthew T Campbell, Arlene O Siefker-Radtke, Neema Navai, Colin P N Di...> ;The Journal of Urology. 2024 Feb 1
• Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
  Omar Alhalabi, Nathaniel Wilson, Lianchun Xiao, Yiyun Lin, Jaanki Khandelwal, Mohammad Jad Moussa, Pavlos Msaouel, Neema Navai, Jianjun Gao, Ashish M Kamat, Patrick Pi...> ;European Urology Oncology. 2023 Dec 1
• 1 citations
  Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
  Arlene O Siefker-Radtke, Diana Cauley, Omar Alhalabi> ;Journal of Clinical Oncology. 2023 Sep 1
• 2 citations
  Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
  Xiaofan Lu, Nassim Tawanaie Pour Sedehi, Xiaoping Su, Fangrong Yan, Omar Alhalabi, Nizar M Tannir, Gabriel G Malouf> ;The Oncologist. 2023 Nov 2
• 1 citations
  Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
  Javier Leo, Eleonora Dondossola, Kaitlin J Basham, Nathaniel R Wilson, Omar Alhalabi, Jianjun Gao, Katherine C Kurnit, Michael G White, Jennifer L McQuade, Shannon N W...> ;Endocrinology. 2023 Apr 17
• 1 citations
  Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
  Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Shizhen Zhang, Apostolia M Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A Yap, David S Hong, M...> ;NPJ Precision Oncology. 2023 Apr 18
• 1 citations
  Evolving systemic management of urothelial cancers.
  Wei Shen Tan, Mae-Yen Tan, Omar Alhalabi, Matthew T Campbell, Ashish M Kamat, Jianjun Gao> ;Current Opinion in Oncology. 2023 May 1
• 4 citations
  Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
  Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W Hahn, Mehmet Asim Bilen, Pavlos Msaouel, ...> ;The Oncologist. 2023 May 8
• Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
  Iuliia Kovalenko, Wern Lynn Ng, Yimin Geng, Yinghong Wang, Pavlos Msaouel, Shailender Bhatia, Petros Grivas, Raed Benkhadra, Omar Alhalabi> ;Frontiers in Oncology. 2023 Jan 1
• 2 citations
  The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
  Antonio Pizuorno Machado, Hunter Ratliff, Ahmed Abdelwahab, Muhammad H Vohra, Andrew Kuang, Menhaz A Shafi, Anusha S Thomas, Jessica Philpott, Omar Alhalabi, Yinghong ...> ;Journal of Cancer. 2023 Jan 1
• 3 citations
  Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
  Alice Saji, Maneera Chopra, Jake Jacob, Mehmet Altan, Omar Alhalabi, Amishi Yogesh Shah, Wei Qiao, Yinghong Wang, Anusha Thomas> ;Journal of Cancer Research and Clinical Oncology. 2023 Aug 1
• 1 citations
  Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
  Omar Alhalabi, Matthew T Campbell, Funda Meric-Bernstam, Altameemi, L.> ;Cancer Journal. 2022 Nov 16
• 1 citations
  Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients.
  Antony Mathew, Zongshan Lai, Dongfeng Tan, Isabella C Glitza Oliva, Jianbo Wang, Omar Alhalabi, Hao Chi Zhang, Anusha Thomas, Yinghong Wang, Malek Shatila> ;Journal of Cancer Research and Clinical Oncology. 2023 Jul 1
• 2 citations
  Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.
  Cynthia Liu, Rajan Amin, Nicholas Short, Mehmet Altan, Amishi Shah, Omar Alhalabi, Pablo Okhuysen, Anusha S Thomas, Yinghong Wang, Malek Shatila> ;Journal of Cancer Research and Clinical Oncology. 2023 Jul 1
• 9 citations
  Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
  Jonathan Thouvenin, Omar Alhalabi, Maria Carlo, Lucia Carril-Ajuria, Laure Hirsch, Nieves Martinez-Chanza, Sylvie Négrier, Luca Campedel, Dylan Martini, Delphine Borch...> ;The Oncologist. 2022 Dec 9
• 20 citations
  MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
  Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lu, Qi Wang, Sumankalai Ramachandran, Rebecca Slack Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh ...> ;Nature Communications. 2022 Apr 4
• 2 citations
  Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.
  Omar Alhalabi, Matthew T Campbell, Lianchun Xiao, Ana C Adriazola, Nathaniel R Wilson, Arlene O Siefker-Radtke, Paul G Corn, Amado Zurita, Eric Jonasch, Jianjun Gao, M...> ;BJUI Compass. 2022 Jan 1
• Reply by Authors.
  Patrick J Hensley, Kelly K Bree, Matthew T Campbell, Omar Alhalabi, Andrea Kokorovic, Tanner Miest, Graciela M Nogueras-Gonzalez, Jianjun Gao, Arlene O Siefker-Radtke,...> ;The Journal of Urology. 2021 Nov 1
• 68 citations
  9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
  Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Zin Thein, Benjamin S. Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang, Minghao Dang, Enyu Dai, S...> ;Nature Communications. 2021 Sep 23
• 8 citations
  Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.
  Jonathan Thouvenin, Nieves Martinez Chanza, Omar Alhalabi, Herve Lang, Nizar M. Tannir, Philippe Barthélémy, Gabriel G. Malouf> ;Cancers. 2021 Aug 27
• Join now to see all

Lectures

• Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma (UBC). 
  2019 ASCO Annual Meeting - 6/1/2019